lc15-0444 and Acute-Kidney-Injury

Cisplatin is a potent chemotherapeutic agent, but its nephrotoxicity, which results in acute kidney injury (AKI), often limits its clinical application. Although many studies have attempted to target the mechanism responsible for its nephrotoxicity, no such method has been demonstrated to be effective in clinical trials. Recently, a dipeptidyl peptidase-4 (DPP4) inhibitor has been reported to have a renoprotective effect in a mouse model of cisplatin-induced AKI. Therefore, we will evaluate whether a DPP4 inhibitor protects the kidney from cisplatin-induced injury in humans.. This is a single-center, prospective, randomized, double-blind, placebo-controlled trial. A total of 182 participants who are scheduled for cisplatin treatment will be enrolled and randomly assigned to receive either a DPP4 inhibitor (gemigliptin) or a placebo. Participants will take the study drugs for 8 days starting 1 day before cisplatin treatment. The primary outcome of interest is the incidence of AKI at 7 days after finishing treatment with cisplatin. The secondary outcomes include changes in serum creatinine levels and estimated glomerular filtration rates from baseline to 7 days after cisplatin treatment.. This is the first clinical trial to investigate the effect of a DPP4 inhibitor on cisplatin-induced AKI.. ClinicalTrials.gov number NCT02250872, December 26, 2014.

Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Cisplatin; Clinical Protocols; Creatinine; Cytoprotection; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Piperidones; Prospective Studies; Pyrimidines; Republic of Korea; Research Design; Time Factors; Young Adult

Topics: Acute Kidney Injury; Animals; Apoptosis; Disease Models, Animal; Doxorubicin; Humans; Inflammation; Kidney Diseases; Male; Membrane Proteins; Mice; Oxidative Stress; Piperidones; Pyrimidines; Repressor Proteins; WT1 Proteins